Adefovir

Hepatitis B Virus Infection

Tongji UniversitySmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

22 Active assets in the Hepatitis B Virus Infection cohort.

Asset / Sponsor	Phase	Rating
Entecavir Sun Yat-sen University	Phase 4	BBB
Lamivudine Fudan University	Phase 4	BBB
Tenofovir Ruijin Hospital	Phase 4	BB
Hepatitis B Virus Vaccine Eunice Dube	Phase 4	BB
Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester West China Hospital	Phase 4	BB

View all 42 →

Same molecule, other indications

Adefovir is also rated in:

hepatocellular carcinomaDormant

BBB

Indicative · Phase 4

75 / 100

cirrhosis of liverDormant

BB

Indicative · Phase 4

65 / 100

HIV infectious diseaseDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.